MedPath

Enitociclib

Generic Name
Enitociclib
Drug Type
Small Molecule
Chemical Formula
C19H18F2N4O2S
CAS Number
1610408-97-3
Unique Ingredient Identifier
1255AT22ZJ
Clinical Trials
Related News

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Phase 1
Active, not recruiting
Conditions
Non-Hodgkin Lymphoma
NHL
Hematologic Malignancies
Lymphoid Malignancies
Lymphoma
Interventions
Device: Vysis LSI MYC Break Apart Rearrangement Probe Kit
Diagnostic Test: PET
Diagnostic Test: EKG
Diagnostic Test: ECHO
Diagnostic Test: CT neck chest, abdomen, and pelvis
Diagnostic Test: MRI
Procedure: Bone marrow aspiration/Biopsy
First Posted Date
2022-05-12
Last Posted Date
2025-04-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
8
Registration Number
NCT05371054
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Phase 1
Terminated
Conditions
MYC Overexpression
MYC Translocation
Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Relapsed Non Hodgkin Lymphoma
Richter Syndrome
MYC Amplification
Interventions
Drug: BTKi
First Posted Date
2021-07-27
Last Posted Date
2023-11-18
Lead Sponsor
Vincerx Pharma, Inc.
Target Recruit Count
6
Registration Number
NCT04978779
Locations
🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇺🇸

The Ohio State University, Columbus, Ohio, United States

and more 2 locations

Phase I Trial of BAY1251152 for Advanced Blood Cancers

Phase 1
Completed
Conditions
Hematologic Neoplasms
Interventions
First Posted Date
2016-04-20
Last Posted Date
2019-09-19
Lead Sponsor
Bayer
Target Recruit Count
21
Registration Number
NCT02745743
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy